Looks like you’re on the UK site. Choose another location to see content specific to your location
Takeda reports positive real-world study data for Entyvio
Takeda has presented the findings of a number of real-world studies that demonstrate the benefits offered by its drug Entyvio.
The findings of eight real-world analyses supporting the effectiveness and safety of Entyvio for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease have been presented at the 2017 Digestive Disease Week annual scientific meeting in Chicago.
In one analysis from the VICTORY consortium, Entyvio was found to be associated with a reduced need for surgery among patients with inflammatory bowel disease, depending on when the drug was initiated over a two-year period.
The consortium is a collaboration of ten leading inflammatory bowel disease centres from across the US, with approximately 900 ulcerative colitis and Crohn's disease patients now included in the database.
Professor William Sandborn, chief of the division of gastroenterology at the University of California, San Diego, said: "Real-world evidence plays an important role in helping healthcare providers evaluate a therapy's effectiveness and safety in routine medical practice against clinical trial results."
These findings reinforce the results of the prior GEMINI clinical trial programme and further demonstrate the effectiveness of this treatment.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard